Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
AuthorsKamthan, A G
Lind, Michael J
Steward, William P
Bronchud, M H
Ranson, Malcolm R
AffiliationDepartment of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
Abstract61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had 'limited stage' disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 with mesna on day 1, and etoposide 120 mg/m2 intravenously on days 1 and 2 and 240 mg/m2 orally on day 3. Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed. Complete response rate in limited stage patients was 55% and 16% in extensive stage patients. The partial responses were 38% and 66% respectively. Overall median survival was 10.5 months with 2-year survival of 14%. The corresponding values for limited stage disease were 13 months and 16% and for extensive stage disease 8 months and 13%. Despite the addition of doxorubicin at a somewhat higher dosage than usual in this type of regimen and a policy of no dose reduction, toxicity was generally mild. There was, however, a 19% relapse rate in complete responders in the brain, apparently as the sole site of disease.
CitationIfosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis. 1990, 26 (6):691-4 Eur J Cancer
JournalEuropean Journal of Cancer
- Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
- Authors: Skarlos DV, Samantas E, Pectasides D, Pavlidis N, Kalofonos C, Klouvas G, Panoussaki E, Tsiakopoulos E, Poulakis N, Fountzilas G
- Issue date: 1999 Feb
- Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
- Authors: Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H
- Issue date: 1989 Feb
- Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
- Authors: Thomas CR Jr, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB
- Issue date: 1998 Mar 15
- The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
- Authors: Cantwell BM, Bozzino JM, Corris P, Harris AL
- Issue date: 1988 Feb
- A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.
- Authors: Woo IS, Park YS, Kwon SH, Park YL, Lee JA, Park MJ, Hyun IG, Jung KS, Bae HS, Oh DH, Kim WS, Park K, Park CH, Kim HJ, Ahn YC
- Issue date: 2000 Dec